This is an effort to lower acid rain and SOx pollution. The particulates and dirty air will remain the same.
When I queried management about the article they felt it was one step closer to adopting gasification systems
When you read about the SES process you understand we remove sulfur in the process of making syngas and the sulfur comes out as an element! They actually sell the sulfur. Gassification does not put sulfur in the atmosphere and can use the coal with the highest sulfur content.
There is tremendous dirty coal usage around Beijing by power plants and small business.They are all basically choking the population. I feel it will not be long until SES has the proof and they now have big enough partners to make it change.
About methanol prices. Not a big factor for me. Just get the GE done. Problem is dealing with Pakistan.
Ask our DOD how much fun that is!
Wrong reason....They keep Mulroy running the company and he has zero credibility with investors.
The Harvard- MIT gang at their best. Crocker has tons invested here and he lets Mulroy run this thing into the ground. We are 6 1/2 months into he year and he told several he was going to have 3 deals this year.
He is minus one..Sanofi.
Why do I own this stock?
Good thought..One day the guy will sell and it will open up $3.00 on a GE deal or something else..Trading for pennies is like trying to run through raindrops...
Also this just adds to the story that was in the New York Time a month ago. If the vagus nerve it the target and potential remedial area we are in a sweet spot.
I know ETRM saw some good results similar to those in the clinical trial you are citing but they did not test for them.They did show lower glucose levels and lowered blood pressure.
I think them mentioned them at the conference call. If this trial you cite has those results it just confirms what occurred in the trials ETRM did. Fascinating and great research on your part.
FDA ordered a sham it seems...This will be like bariatric..It changes a lot of metabolic events. Why operate from within the stomach? Seems rather complicated.
The USGI procedure is still quite invasive and only seem to remedy the cutting of a bariatric
procedure. How they plan a sham procedure will be quite interesting. Interesting though. USGI and ETRM both started in Europe. But it is funny, Europe does not have the obesity problem the U.S. has,and socialized medicine will pay the freight.
I will watch with interest. The sham control arm will be of interest. Private companies do have a bit
of leeway as far as information is concerned.
Friday' s Wall Street Journal had an editorial by Dr. Marty Makary from Johns Hopkins extolling the virtues of laproscopic surgery, " A Minimally Invasive Approach to Health Care Reform." Maybe the FDA sees the same dilemma when looking at VBLOC versus bariatric.
They are capitalized leases you idiot...If they borrow short term they have paid it off with stock issuance.
Please get lost. Everything you cite is public record. Why don't you call some of the institutional investors and ask them your sophomoric questions.
You are an idiot..get lost
You state the correct theme..Long term investors are patient. Knudson knows what he is doing. This is not a short term play. They have a technology base. I will be very disappointed if they sell this science. If they promote this device before FDA approval they are making a mistake The FDA pays attention to everything said and done by the company before approval. I know. I have been there and seen it.
DNDN had a drug..we have a device..DNDN Provenge is useless and the stock price shows it.
ETRM has a device that will be a boomer....
How much capital did Amgen spend before its first product? You can look at any 10Q or 10K from any
developmental company and read the same things. You take us for idiots? ETRM does not have 200 Million shares outstanding like a lot of companies.Take your pals at ARNA. They have 216 Million shares outstanding an a 1.2 Billion loss carry forward. I could go into 200 balance sheets and get the same data you get from ETRM.
Your analysis is bogus. You have no idea what you are talking about. The way a company raises capital and how it develops its products is simple finance which you do not understand. How would you have them operate away from selling stock? And a shelf registration? You read 10Q boilerplate statements and assume none of us know what is occurring.
One trick pony?? Sure, but it is a trick that is going to make the company worth a great deal.
Before you opine first get an understanding of how small developmental device companies and biotechs
operate. I suggest you wait for the the FDA decision then tell us now smart you were to sell. Your 10Q
diatribe is useless.
Endoscopic surgery is easier to teach than filling a cavity. It is air, a camera, and two 1/2 inch holes. My gastroenterologist told me it would take him and hour or two to learn the procedure. But this will be done by surgeons and those guys are quick learners when the money bell goes off. Orthopaedic guys do 10 knees a day.
They have to disclose a partner. That is not scientifically sensitive. And why wouldn't they disclose that!!!!!! I have waited 3 years for Mulroy to find a partner. All he has done is lose one!
It is not a knife..you seem to know very little about endoscopic procedures. And for the future, patients know what a scope will do and a non-invasive device. They still have no idea what a pill will do. How do you defend ARNA's pathetic sales so far? They have been on the market a while now. Save your money. Buy ARNA leaps.